Drug class
Adeno-associated virus serotype 5 (AAV5) gene therapy delivering the factor IX Padua variant (FIX-Padua)
Mechanism of action
AAV5 vector delivers a functional F9 gene encoding the Padua variant of human coagulation factor IX to hepatocytes, enabling endogenous production of factor IX with increased specific activity and supporting haemostasis.
General use cases
- Treatment of adults with haemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis, have a history of life-threatening haemorrhage, or have repeated serious spontaneous bleeding episodes, subject to product-specific criteria
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
